Diametric Capital’s Cartesian Therapeutics RNAC Stock Holding History

Diametric Capital’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-38,069	Closed	-$234K	–	655
2026 Q1	$234K	Buy	+38,069	New	+$271K	0.06%	370

Other funds holding RNAC

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Diametric Capital's RNAC Position: Q2 2026 in Review

Diametric Capital sold out of Cartesian Therapeutics (RNAC) in Q2 2026, closing a stake of 38,069 shares — an estimated $234K sold.

Diametric Capital first reported a position in RNAC in Q1 2026 and held it in 1 quarter. The position peaked at $234K in Q1 2026. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

Diametric Capital reported no remaining Cartesian Therapeutics position as of Q2 2026 after selling out during the quarter.
Diametric Capital sold 38,069 Cartesian Therapeutics shares in Q2 2026, an estimated $234K.
Diametric Capital first reported a position in Cartesian Therapeutics in Q1 2026 and held it in 1 quarter.
Diametric Capital's Cartesian Therapeutics position peaked at $234K in Q1 2026.
95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.